Back to Supplement Score
56
SCORE

Oleoylethanolamide (OEA)

Satiety · Metabolic · Endocannabinoid-like
Tier 3 — Trending

What it is

A monounsaturated fatty acid ethanolamide produced endogenously in the small intestine during fat ingestion, acting at PPAR-alpha to signal satiety. Oral supplementation in humans modestly reduces food intake, waist circumference, and LDL. Structurally related to the endocannabinoid anandamide but does not activate cannabinoid receptors — instead it suppresses appetite via PPAR-alpha. A complementary mechanism to GLP-1 agonists and fibre. Safety profile in short-term trials is good but long-term data are limited.

Efficacy
2/5
Safety
4/5
Research
2/5
Onset
3/5
Cost
3/5
Drug-int.
4/5

Dose

100–300 mg before meals, 1–3 times daily

Time of day & tips

Take 30 min before meals for appetite effect; evidence is modest but mechanism is well-characterised; synergistic with fibre and protein for satiety

Compare or learn more

Compare with another supplement →
Browse by symptom →
Open the full interactive view →

Educational reference, not medical advice. About · Methodology · Privacy · Terms